

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/120213 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 31/513* (2006.01)
A61K 31/137 (2006.01) *A61K 31/60* (2006.01)
A61K 31/201 (2006.01) *A61K 33/04* (2006.01)
A61K 31/343 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4174 (2006.01) *A61P 17/00* (2006.01)
A61K 31/44 (2006.01) *A61P 17/04* (2006.01)
A61K 31/496 (2006.01) *A61P 31/10* (2006.01)
A61K 31/506 (2006.01)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/061871

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

03 December 2021 (03.12.2021)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/121,299 04 December 2020 (04.12.2020) US

(72) Inventors; and

(71) Applicants: **BERK, David Reuben** [US/US]; Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite #300, Westlake Village, California 91361 (US). **BURNETT, Patrick Eugene** [US/US]; Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite #300, Westlake Village, California 91361 (US). **OSBORNE, David** [US/US]; 4215 Creekside Court, Fort Collins, Colorado 80525 (US).

(72) Inventor: **KATO, Saori**; Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite #300, Westlake Village, California 91361 (US).

(74) Agent: **KITTS, Monica**; 607 14th Street NW, Suite 800, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES

(57) Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi *Malassezia spp.* Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, *tinea versicolor*, *pityriasis versicolor*, *tinea circinata*, *tinea pedis*, *tinea unguium*, *tinea manus*, *tinea cruris*, *tinea corporis*, *tinea faciei*, *tinea capitis*, and/or *tinea incognito*. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.



WO 2022/120213 A1